These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 17141360

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
    Bianchini D, Jayanth A, Chua YJ, Cunningham D.
    Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
    [Abstract] [Full Text] [Related]

  • 8. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H.
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [Abstract] [Full Text] [Related]

  • 9. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
    Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME.
    Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
    [Abstract] [Full Text] [Related]

  • 10. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T.
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
    Eames T, Grabein B, Kroth J, Wollenberg A.
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):958-60. PubMed ID: 20015177
    [Abstract] [Full Text] [Related]

  • 14. Common side effects of anti-EGFR therapy: acneform rash.
    Sipples R.
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
    [Abstract] [Full Text] [Related]

  • 15. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
    Fox LP.
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
    [Abstract] [Full Text] [Related]

  • 16. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME.
    Oncology; 2007 Apr; 72(3-4):152-9. PubMed ID: 18160805
    [Abstract] [Full Text] [Related]

  • 17. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.
    Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, Lacouture ME.
    J Am Acad Dermatol; 2012 Nov; 67(5):1025-39. PubMed ID: 22502948
    [Abstract] [Full Text] [Related]

  • 18. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R, Werfel T, Kapp A, Elsner J.
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [Abstract] [Full Text] [Related]

  • 19. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J, Arteaga CL.
    J Clin Oncol; 2005 Apr 10; 23(11):2445-59. PubMed ID: 15753456
    [Abstract] [Full Text] [Related]

  • 20. EGFR-targeted therapy and related skin toxicity.
    Morse L, Calarese P.
    Semin Oncol Nurs; 2006 Aug 10; 22(3):152-62. PubMed ID: 16893744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.